A Phase 1b, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Failed Prior Therapies
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Imvotamab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors IGM Biosciences
Most Recent Events
- 09 Jan 2025 Status changed from recruiting to discontinued, according to an IGM Biosciences media release.
- 08 Nov 2024 According to an IGM Biosciences media release, initial clinical data disclosure expected by mid-2025.
- 08 Nov 2024 According to an IGM Biosciences media release, third dose cohort in rheumatoid arthritis successfully completed.